The stock of Olema Pharmaceuticals Inc (NASDAQ:OLMA) last traded at $6.45, up 2.38% from the previous session.
OLMA stock price is now -35.39% away from the 50-day moving average and -43.07% away from the 200-day moving average. The market capitalization of the company currently stands at $362.13M.
With the price target of $24, Goldman recently initiated with Buy rating for Olema Pharmaceuticals Inc (NASDAQ: OLMA). On January 30, 2024, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $20, while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Graham G. Walmsley, Director sold 700,761 shares of the company’s stock on Dec 17 ’24. The stock was sold for $4,730,137 at an average price of $6.75. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 13 ’24, Affiliate Logos Opportunities Fund I LP bought 700,761 shares of the business’s stock. A total of $4,730,137 was incurred on buying the stock at an average price of $6.75. A total of 25.17% of the company’s stock is owned by insiders.
During the past 12 months, Olema Pharmaceuticals Inc has had a low of $5.56 and a high of $16.77. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 7.10, and a quick ratio of 7.10. The fifty day moving average price for OLMA is $10.0918 and a two-hundred day moving average price translates $11.36305 for the stock.
The latest earnings results from Olema Pharmaceuticals Inc (NASDAQ: OLMA) was released for 2024-09-30.
